Hansa Biopharma (Q4 initial take): Strong European Sales Beats Forecast - Redeye
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat of our estimate. IDEFIRIX sales amounted to SEK61m. We expect a positive share price reaction.
ANNONS
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat of our estimate. IDEFIRIX sales amounted to SEK61m. We expect a positive share price reaction.
